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Abstract
Human breast milk provides all necessary nutrients for the development of term 
infants. In addition to its universally recognized nutrients, human breast milk con-
tains a number of non-nutritive components that play a potential role in supporting 
infant growth. Human breast milk also contains bioactive compounds exerting a 
wide range of beneficial effects, such as promoting immune system maturation 
and exerting protection against infections. Supplementation of infant formulae 
with oligosaccharides and bacteria with proven beneficial health effects seems to be 
well-founded. The purpose of supplementation is to mimic the functional effects of 
oligosaccharides and bacteria found in human breast milk. Oligosaccharides with 
prebiotic functions and bacteria strains with probiotic functions have recently been 
added to infant formulae in the European Union and other countries. However, 
a systematic review conducted by the Committee on Nutrition of the European 
Society for Pediatric Gastroenterology, Hepatology, and Nutrition revealed that 
there is no conclusive evidence supporting the routine use of probiotic- and/or 
prebiotic-fortified infant formulae. The aim of this review is to analyze the scien-
tific basis for supplementation of infant formula with these compounds.
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1. Introduction
Human breast milk (HBM) is a complex physiological fluid uniquely suited to 
nourish infants. Its composition is specifically adapted to the digestive system and 
nutritional and growth needs of infants. HBM does not only contain essential nutri-
ents, but also a vast array of non-nutritional bioactive components and microbes 
(microbiota) that confer benefits to the health of infants in the short and long terms. 
The microbiota mediates bacterial colonization of the newborn gut and supports 
immune system maturation and metabolic and cognitive development. Protective 
constituents such as cytokines, oligosaccharides, and bacteria facilitate newborn’s 
adaptation to the extrauterine environment [1, 2]. HBM has been long known to 
protect neonates and infants from infections. It has been suggested that this pro-
tective role could be regulated by the action of a group of components that might 
inactivate bacteria and viruses individually, additively, and synergistically [3].
Gut microbiota has effects on health, and HBM contributes decisively to its com-
position via its bacteria and oligosaccharides supply. In order to achieve the same 
health effects, infant formulae are supplemented with live bacteria (probiotics), 
which favor bifidobacteria and lactobacilli growth (prebiotics) or a combination of 
these components (symbiotics).
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2. Gut microbiota
Our body hosts a vast, diverse community of stable and varying microorganisms 
that are referred to as microbiota. The gut is the niche with the highest number and 
diversity of micro-organisms, containing over 1014 microbial cells, 10 times the 
amount of somatic and germinal cells in our body. The microbes that inhabit our 
gut are known as gut microbiota [4].
Gut microbiota is an open ecosystem that contains a broad diversity of meta-
bolically active microbes that coexist in space and time and play a relevant role in 
the health of their host. The gut microbiota is considered a metabolic organ that is 
adaptable and rapidly renewable. There is a mutually beneficial interplay between 
the host and gut microbiota [4, 5].
2.1 Gut microbiota and immunity
The relationship between the lymphatic system and gut microbiota in early 
stages of life is crucial to the appropriate development of interactions between 
mucosal cell communities and systemic immunomodulation [5]. Animals with a 
sterile gut have been proven to be highly vulnerable to infections, which demon-
strate the important role that gut microbiota plays in the immune system [4].
Bacterial colonization of the newborn’s gut is influenced by a variety of factors 
such as gestation and delivery and breast-feeding mode [6]. HBM is an excellent con-
tinuous source of commensal bacteria for the infant gut. Evidence has been provided 
of a vertical transfer of bacteria from mother to child via breast milk [7, 8]. The fact 
that facultative anaerobic bacteria in newborn’s gut are the predominant bacterial 
community in HBM microbiota is not a chance. These bacteria play a key role in the 
prevention of infections in the newborn [9]. Gut microbiota disorders (dysbiosis) in 
the first stages of life reportedly precede the development of atopy [10].
During the first week of life, the total bacterial count and, more specifically, 
anaerobic bacteria count progressively increase. The feeding mode of the newborn 
has a decisive impact on bacterial gut colonization. Bifidobacteria, lactobacilli, and 
Gram-positive cocci predominate in the feces of breastfed infants, whereas the 
bifidobacteria count is lower in the feces of formula-fed infants, with the predomi-
nance of bacteroides, clostridia, and coliforms [11–13]. Differences in the composi-
tion of newborn’s gut microbiota based on the type of feeding could be the clue to 
identifying the bacteria that exert protective effects to breastfed infants [4].
3. Probiotics
Bacterial concentrations in HBM range between 102 and 104 ufc/mL. This means 
that an infant ingesting over 800 ml of milk a day would receive 105 to 107 ufc [14]. 
Therefore, HBM is a primary source of commensal and probiotic bacteria to the 
infant and plays a key role in the initial colonization of the gut. Some bacteria 
isolated from HBM have proven to have immunomodulatory and anti-infective 
effects. Therefore, the protective effects of HBM may be conferred by these bacte-
ria. Supplementation of infant formulae with probiotic bacteria isolated from HBM 
could help improve gut microbial balance in formula-fed infants, thereby mimick-
ing the beneficial effects of HBM.
Evidence has been published that probiotics modulate mucosal and systemic 
immune function, improve intestinal barrier function, and exert metabolic effects 
on the host [4]. Some of the lactobacillus strains isolated from HBM [15] have been 
reported to compete with enteropathogenic bacteria for nutrients and epithelium 
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adhesion and improve gut barrier functions. The ability of lactobacillus and bifido-
bacteria strains to stabilize the integrity of gut barrier has been demonstrated [16]. 
These types of bacteria potentially reduce antigen systemic load and influence 
immune function via enterocytes, antigen-presenting cells (monocytes and den-
dritic cells), regulatory T cells, and effector T and B cells [17, 18].
3.1 Infant formula supplemented with probiotics
European Society for Pediatric Gastroenterology, Hepatology, and Nutrition 
(ESPGHAN) Committee on Nutrition [19] published a systematic review of studies 
assessing the safety and health effects of probiotic-supplemented infant formulae. 
No conclusive data were obtained from ESPGHAN’s analysis of infant and follow-on 
formulae due to considerable variability in the type and dose of probiotics used and 
supplementation periods.
3.1.1 Safety
Formulae supplemented with probiotics do not raise safety concerns with regard 
to growth and adverse effects [19]. There are sufficient data supporting the safety 
of probiotics for infants older than 6 months. However, data on the use of probiotic 
supplementation in infants younger than 4 months are more limited. Studies in 
breastfed infants younger than 6 months who received a formula supplemented 
with either Lactobacillus fermentum CECT5716 or Lactobacillus rhamnosus GG 
revealed that formulae were well tolerated and had no adverse effects on growth 
either during the study period or at 3–5 years of age [20–23]. A recent study 
revealed that growth and food tolerance improved in premature infants >30 weeks 
of gestational age fed with a formula supplemented with Saccharomyces boulardii, 
and no adverse effects were detected [24].
3.1.2 Prevention and treatment of infant disorders
Conflicting results have been obtained regarding the effects of probiotics on 
the composition of fecal microbiota. A decrease in bifidobacteria and enterobac-
teria concentrations has been reported with respect to controls [25, 26]. Also, 
no differences have been observed in lactobacillus and bacteroides. By contrast, 
Maldonado et al. [27] reported an increase in fecal bifidobacteria and lactobacilli 
concentrations in infants fed with a formula supplemented with Lactobacillus 
fermentum CECT 5716. Also, no differences were found in other bacteria strains. 
Evidence has been provided that a formula containing Bifidobacterium lactis can 
influence the composition, stability, and function of gut microbiota in low-weight 
newborns [28].
The literature reports that probiotic supplementation of formula beyond early 
infancy can produce a decrease in the use of antibiotics and incidence of diarrhea, 
colic, and/or irritability. Yet, the variety of methods, type and dose of probiotics, 
and duration of interventions hinders that conclusive data can be obtained on 
clear clinical effects of probiotic-supplemented formulae in infants younger than 4 
months [19].
In general, there is no consistent evidence supporting that supplementation 
of follow-on formula with probiotics has protective effects against infectious diar-
rhea [19]. Yet, a reduction has been reported in the duration and number of episodes 
of diarrhea associated with the use of probiotic-supplemented formulae [27, 29–31].
A systematic review conducted by Mugambi et al. [32] of controlled, ran-
domized trials did not reveal that supplementation had any effects on infectious 
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diarrhea, colic, crying/irritability, regurgitation, or vomiting. No beneficial effects 
were documented on either crying or irritability in the review by ESPGHAN 
Committee on Nutrition. A study that was not included in ESPGHAN study showed 
that colic symptoms substantially improved with the administration of Lactobacillus 
reuteri DSM 17938 in breastfed infants [33]. There is no sufficient evidence, how-
ever, supporting routine supplementation with probiotics for the treatment or 
prevention of colic, especially in formula-fed infants [34].
In a review on the effects of a variety of immunonutrients in the prevention 
of necrotizing enterocolitis [35], the authors gathered sufficient data supporting 
supplementation of infant formulae with probiotics. Several meta-analyses com-
bined these randomized controlled trials and observational studies demonstrated 
that the use of probiotics was beneficial for the prevention of severe necrotizing 
enterocolitis, late-onset sepsis, and all-cause mortality in very-low-birth-weight 
infants, as well as the time to achieve full enteral feeding in preterm infants 
[36–38]. By contrast, no differences were observed in a multicenter study involving 
1315 preterm newborns fed with a hydrolyzed formula supplemented and non-
supplemented with the probiotic Bifidobacterium breve BBG-001 [39]; the results of 
this trial provide no evidence of benefit of this probiotic intervention in reducing 
late-onset sepsis and necrotizing enterocolitis or death.
In relation to respiratory infections, limited available evidence from randomized 
controlled trials showed that formula supplementation with the probiotics studied 
is not associated with a reduction in the duration or risk of respiratory infections 
[19, 32]. A number of studies on formulae supplemented with different probiotic 
bacteria [30, 27, 40, 41] have shown a significant reduction in the number of upper 
airway tract infections in infants fed with these formulae. A study on Lactobacillus 
fermentum CECT 5716 [27] reports a significant 30% reduction in the total number 
of infections.
Significant reductions have been documented in the incidence of influenza and 
respiratory symptoms in several studies, where Lactobacillus fermentum CECT 5716 
was administered in combination with anti-influenza vaccine [42]. This effect is 
explained by increased levels of NK cells and T-helper and T-cytotoxic lymphocytes.
Sufficient evidence has not been published supporting the beneficial effects 
of supplementation of infant formulae with probiotics on allergies. Several meta-
analyses, however, have shown that the use of probiotics reduces the incidence of 
atopic dermatitis in infants but not of other types of allergies [43–45].
Evidence has been published that dietary treatment with a extensively hydro-
lyzed formula containing Lactobacillus rhamnosus GG is associated with a higher 
rate of acquisition of tolerance in infants allergic to cow’s milk proteins, as com-
pared to infants treated with a non-supplemented hydrolyzed formula [46, 47]. A 
relationship has been documented between dysbiosis in gut microbiota composition 
and the pathogenesis of cow’s milk allergy [48, 49]. In addition, the administration 
of a hydrolyzed formula supplemented with probiotics reduces the incidence of 
other allergies and favors tolerance, as it changes the composition of infant’s gut 
microbiota [23, 50].
Some studies suggest that gut microbiota alterations precede the development 
of the allergic phenotype. Therefore, probiotics could exert preventive and thera-
peutical effects [51]. The potential of some strains to favor Th1 and Th3 immune 
response against Th2 activity in patients with atopy can create the optimal condi-
tions to redirect immune memory and reduce the risk of atopic disease. The Work 
Allergy Organization (WAO) [52] determined that probiotics confer health benefits 
in the prevention of eczema. Thus, WAO recommends the use of probiotics in preg-
nant or breastfeeding women whose infants have a high risk of developing allergies 
and in infants with a high risk of allergy.
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3.1.3 Conclusion
ESPGHAN Committee on Nutrition does not recommend the routine use of 
infant formulae supplemented with probiotics. However, the evidence obtained 
in recent studies suggests that infant formulae containing some specific bacteria 
strains can confer beneficial health effects. A large number of infant formulae cur-
rently available on the market contain probiotics, and several panels support their 
use provided that their safety and benefits for the health and development of the 
infant have been demonstrated [19, 53, 54]. The European Food Safety Authority 
(EFSA) supports the safety of formula supplementation with probiotic bacteria. 
Yet, EFSA recommends that further studies are conducted to obtain the highest 
quality evidence on their efficacy [55].
4. Prebiotics
Prebiotics are defined as oligosaccharides refractory to the human digestive 
process with ability to stimulate and promote the growth and/or metabolism of 
bifidobacteria and lactobacilli in human gut [56]. More than 200 oligosaccharide 
complexes (neutral and cyclical oligosaccharides) have been identified in human 
breast milk [57]. Neutral oligosaccharides account for 70% of the total count 
and include the isomers lacto-N-tetraose, lacto-N-neotetraose, lacto-N-hexaose, 
monofucosyl-lacto-N-hexaose, and difucosyl-lacto-N-hexaose. Low levels of acidic 
oligosaccharides containing sialic acid or sulfate groups are present in HBM, and 
they primarily contain 5-N-acetyl-neuraminic acid [58].
Colostrum is composed of higher oligosaccharide concentrations (15–23 g/L), 
whereas mature HBM contents range from 1 to 10 g/L [59]. Oligosaccharides 
account for 8% of the total nutrient contents of HBM and are the third prevalent 
component following lactose and lipids.
Most of these oligosaccharides are non-absorbable and reach the colon, where 
they have different functions. Thus, they compete for membrane receptors with 
pathogenic bacteria and viruses in intestinal epithelium; they contribute to acidifi-
cation via fermentation by colon bacteria; inhibit the growth of bacteroides, clos-
tridia, and coliforms; promote lactobacilli and bifidobacteria growth; and stimulate 
the development of infant’s immune system. A direct relationship has been 
documented between oligosaccharides and selectins, integrins, and other recep-
tors, and they mediate leukocyte-endothelial cell interactions [59]. Fermentation 
of prebiotics by gut bacteria produces short-chain fatty acids, which exert a direct 
anti-inflammatory effect and promote intestinal barrier integrity by stimulating the 
proliferation and differentiation of gut mucosal cells.
Cow milk oligosaccharide content is substantially lower than that of HBM, and 
infant formula supplementation with prebiotics with the purpose of obtaining their 
health benefits is well founded. At present, GOS and FOS combinations are used, 
and other HBM oligosaccharides have been recently incorporated to infant formulae.
4.1 Infant formulae supplemented with prebiotics
The European Scientific Committee on Food approved prebiotic supplemen-
tation in infant and follow-on formulate up to a maximum of 0.8 g/100 ml to a 
GOS:FOS ratio of 9:1. By contrast, a systematic review on the safety and health 
effects of prebiotic-supplemented infant formulae conducted by ESPGHAN 
Committee on Nutrition [19] did not provide conclusive evidence due to variability 
in the type and dose of the prebiotic used and period of intervention.
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2′-flucosyllactose, a HBM oligosaccharide, was recently synthesized and has 
been incorporated to some infant formula [60].
4.1.1 Safety
Formulae fortified with prebiotics do not raise safety concerns with regard to 
growth and adverse effects. [19]. Infant formulae containing HBM oligosaccharides 
have proven to be safe and well tolerated, and synthetic oligosaccharides have 
demonstrated to have similar effects to those of HBM oligosaccharides [60].
4.1.2 Prevention and treatment of infant disorders
There is solid evidence that infant formula containing some prebiotics is associ-
ated with less-consistent feces and a higher frequency of defecation [61]. However, 
inconsistent evidence has been obtained on the association between prebiotics and 
the frequency of defecations [32, 62].
The use of prebiotic-fortified formulae has been associated with a lower risk 
for intestinal and respiratory infections [63, 64] and an increase in fecal secre-
tory IgA levels [65]. By contrast, they have not been proven to exert any effects 
on humoral and cellular immunity [66]. In general terms, there is no conclusive 
evidence supporting that supplementation of infant formulae with prebiotics exerts 
any protective effects against infections, colic, crying/irritability, regurgitation, or 
vomiting [19, 32]. Fortification with 2′-flucosyllactose does seem to improve infant 
immunity, as it has been reported to be related to a lower incidence of infections, 
especially respiratory infections [60].
GOS:FOS mixtures favor the growth of bifidobacteria and lactobacilli in the 
feces of infants receiving fortified formulae. However, they have a limited effect on 
the reduction of pathogenic bacteria [19]. Yet, some studies suggest that prebiotics 
reduce pathogenic micro-organism concentrations, while the infant is receiving a 
formula supplemented with oligosaccharides [67]. A number of studies [25, 32, 62] 
have failed to demonstrate that bifidobacteria, lactobacilli, or pathogen count 
decreases with prebiotics.
Other studies have shown similarities between the bifidogenic effect of 
prebiotic-fortified formulae and HBM, as compared to non-fortified formulae 
[59, 68, 69]. Indeed, prebiotics have been reported to have special effects on some 
bifidobacteria species such as Bifidobacterium breve. Thus, fecal Bifidobacterium 
breve concentrations in infants fed with a fortified formula have been documented 
to be similar to those found in breastfed infants.
Although prebiotic-supplemented formulae are thought to prevent eczema 
in infants at high risk of developing allergies [43, 63, 70], there is no sufficient 
evidence on the role that prebiotics play in the prevention of eczema, atopic derma-
titis, or food hypersensitivity [71, 72]. A partially hydrolyzed formula containing 
specific prebiotics has been reported to generate a gut microbiota similar to that of 
breastfed infants. A potential link between microbial activity and eczema onset was 
identified, which could suggest a suboptimal implementation of gut microbiota in 
specific developmental stages of infants at high risk of developing allergy [73].
4.1.3 Conclusion
ESPGHAN Committee on Nutrition does not recommend routine use of infant 
formulae supplemented with prebiotic. In agreement with the American Academy 
of Pediatrics, they recommend that further studies are conducted to assess the 
safety and efficacy of prebiotic supplementation.
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5. Symbiotics
Symbiotics are mixtures of probiotics and prebiotics that beneficially affect 
the host by improving the survival and implantation of the probiotic bacteria 
and stimulate the activity of the host’s endogenous bacteria [56]. Symbiotics are 
believed to act synergistically to increase the overall gut health by offering more 
benefits than the use of either a probiotic or prebiotic agent alone. Considering a 
huge number of possible combinations, the application of symbiotics for the modu-
lation of intestinal microbiota in humans seems promising [74]. A disadvantage to 
using symbiotics is that it is difficult to predict the selectivity and specificity of each 
of the components and what the resulting mechanisms of action will be.
Limited data have been provided on concomitant prebiotic and probiotic 
supplementation of infant formulae. The few studies carried out with symbiotics 
[19, 32, 75] revealed that symbiotics: (a) do not exert effects on growth; (b) do not 
reduce the incidence of digestive disorders (colic, regurgitation, crying, vomiting, 
to name a few) or infections; (c) increase the frequency of daily defecations but do 
not influence fecal consistency; and (d) no data are available on their effects on the 
composition of gut microbiota or on immune response.
There is no conclusive evidence on the effects of supplementation of infant 
formula with symbiotics. Therefore, ESPGHAN Committee on Nutrition does not 
recommend routine use of infant formula fortified with symbiotics.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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